Cargando…

Subtyping of Parkinson’s Disease - Where Are We Up To?

Heterogenous clinical presentations of Parkinson’s disease have aroused several attempts in its subtyping for the purpose of strategic implementation of treatment in order to maximise therapeutic effects. Apart from a priori classifications based purely on motor features, cluster analysis studies ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qian, Elizabeth, Huang, Yue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JKL International LLC 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764738/ https://www.ncbi.nlm.nih.gov/pubmed/31595207 http://dx.doi.org/10.14336/AD.2019.0112

Ejemplares similares

Endogenous versus exogenous cell replacement for Parkinson’s disease: where are we at and where are we going?
por: Mourtzi, Theodora, et al.
Publicado: (2022)

Gene and Cell-Based Therapies for Parkinson’s Disease: Where Are We?
por: Buttery, Philip C., et al.
Publicado: (2020)

Lipidomics of Bioactive Lipids in Alzheimer’s and Parkinson’s Diseases: Where Are We?
por: Chiurchiù, Valerio, et al.
Publicado: (2022)

Venoms as an adjunctive therapy for Parkinson’s disease: where are we now and where are we going?
por: Gazerani, Parisa
Publicado: (2020)

Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now?
por: Rosa-Grilo, Miguel, et al.
Publicado: (2017)

Diagnostic biomarkers for Parkinson’s disease at a glance: where are we?
por: Cova, Ilaria, et al.
Publicado: (2018)

Seeking biomarkers for acute graft-versus-host disease: where we are and where we are heading?
por: Zhao, Xiao-Su, et al.
Publicado: (2019)

Cognitive Interventions in Parkinson’s Disease: Where We Want to Go within 20 Years
por: Kalbe, Elke, et al.
Publicado: (2018)

SARS-CoV-2 and Parkinson’s Disease: A Review of Where We Are Now
por: Boura, Iro, et al.
Publicado: (2023)

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
por: Turnbull, Samantha, et al.
Publicado: (2015)

Animal Sentience: Where are We and Where are We Heading?
por: Proctor, Helen
Publicado: (2012)

Bioactive Glasses: Where Are We and Where Are We Going?
por: Baino, Francesco, et al.
Publicado: (2018)

Diabetic cardiomyopathy: where we are and where we are going
por: Lee, Wang-Soo, et al.
Publicado: (2017)

Hidradenitis Suppurativa: Where We Are and Where We Are Going
por: Scala, Emanuele, et al.
Publicado: (2021)

Vesicoureteral Reflux: Where Have We Been, Where Are We Now, and Where Are We Going?
por: McLorie, Gordon A.
Publicado: (2008)

Obstetric ultrasound: where are we and where are we going?
por: Abramowicz, Jacques S
Publicado: (2021)

Research Integrity: Where We Are and Where We Are Heading
por: Zhaksylyk, Alikhan, et al.
Publicado: (2023)

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?
por: Hasenoehrl, Carina, et al.
Publicado: (2017)

The Pathogenesis and Treatment of Cardiovascular Autonomic Dysfunction in Parkinson’s Disease: What We Know and Where to Go
por: Zhu, Shuzhen, et al.
Publicado: (2021)

Colon Capsule Endoscopy: Where Are We and Where Are We Going
por: Han, Yoo Min, et al.
Publicado: (2016)

Chronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?
por: Hayes, Gemma E., et al.
Publicado: (2016)

Accommodative intraocular lenses: where are we and where we are going
por: Alió, Jorge L., et al.
Publicado: (2017)

Hepatitis C Vaccination: Where We Are and Where We Need to Be
por: Manne, Vignan, et al.
Publicado: (2021)

Osteoarthritis and Diabetes: Where Are We and Where Should We Go?
por: Alenazi, Aqeel M., et al.
Publicado: (2023)

Biomarkers of Neonatal Sepsis: Where We Are and Where We Are Going
por: Boscarino, Giovanni, et al.
Publicado: (2023)

Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going
por: Liu, Eleanor, et al.
Publicado: (2022)

Designing Socially Assistive Robots for Alzheimer’s Disease and Related Dementia Patients and Their Caregivers: Where We Are and Where We Are Headed
por: Koutentakis, Dimitrios, et al.
Publicado: (2020)

Research on Service-Learning in Physical Activity and Sport: Where We Have Been, Where We Are, Where We Are Going
por: Francisco-Garcés, Xavier, et al.
Publicado: (2022)

Deep Brain Stimulation for Parkinson's Disease: Where Do We Stand?
por: Albanese, Alberto, et al.
Publicado: (2011)

Male contraception: where are we going and where have we been?
por: Reynolds-Wright, John Joseph, et al.
Publicado: (2019)

Critical care - where have we been and where are we going?
por: Vincent, Jean-Louis
Publicado: (2013)

Lifestyle Factors in Cancer Survivorship: Where We Are and Where We Are Headed
por: Vijayvergia, Namrata, et al.
Publicado: (2015)

Aging with Down Syndrome—Where Are We Now and Where Are We Going?
por: Alldred, Melissa J., et al.
Publicado: (2021)

Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
por: Jang, Albert, et al.
Publicado: (2021)

Artificial Intelligence in Digestive Endoscopy—Where Are We and Where Are We Going?
por: Vulpoi, Radu-Alexandru, et al.
Publicado: (2022)

Alopecia Areata in Latin America: Where are We and Where are We Going?
por: Velásquez-Lopera, Margarita M., et al.
Publicado: (2022)

The peritumoral brain zone in glioblastoma: where we are and where we are going
por: Giambra, Martina, et al.
Publicado: (2022)

Where Are We and Where to Next?—The Future of Perianal Crohn’s Disease Management
por: Anandabaskaran, Sulak, et al.
Publicado: (2023)

Diversity in orthopaedic trauma: where we are and where we need to be
por: Ortega, Gil, et al.
Publicado: (2021)

Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going
por: Taveira-DaSilva, Angelo M, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_gkq7s1bnb8fmofh3t6di9m7l49